A United Kingdom study evaluating changes of quality of life for patients with GLP1-RA demonstrated that the therapy significantly reduced the Hospital Anxiety and Depression Scale (HADS) scores, compared with insulin-treated patients. This evidence concerns the gene GLP1R and depressive disorder.